Life Sciences Division, TRIUMF, Vancouver, British Columbia, Canada;
Department of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada.
J Nucl Med. 2021 Nov;62(11):1495-1503. doi: 10.2967/jnumed.120.261016. Epub 2021 Jul 22.
Encouraging results from targeted α-therapy have received significant attention from academia and industry. However, the limited availability of suitable radionuclides has hampered widespread translation and application. In the present review, we discuss the most promising candidates for clinical application and the state of the art of their production and supply. In this review, along with 2 forthcoming reviews on chelation and clinical application of α-emitting radionuclides, will provide a comprehensive assessment of the field.
靶向 α 疗法的可喜成果引起了学术界和工业界的广泛关注。然而,合适的放射性核素的有限可得性阻碍了其广泛的转化和应用。在本综述中,我们讨论了最有前途的临床应用候选物以及它们的生产和供应的最新进展。与即将发表的两篇关于螯合和α发射放射性核素临床应用的综述一起,本文将对该领域进行全面评估。